Proteostasis Stock at Bottom of Nasdaq After Drug Data, Downgrade

Early data for PTI's cystic fibrosis treatment disappointed analysts

Managing Editor
Jun 7, 2018 at 10:16 AM
facebook twitter linkedin


Proteostasis Therapeutics Inc (NASDAQ:PTI) has fallen to the bottom of the Nasdaq this morning, down 35% to trade at $3.19, after early stage data for the company's cystic fibrosis treatment disappointed analysts -- specifically, its inability to improve lung function. In response, RBC downgraded PTI stock to "sector perform" from "outperform," while more than halving its price target to $5 from $11. 

Looking closer at the charts, PTI stock hit an annual high of $8.61 back in March, before gapping lower in the wake of a scathing short seller report. The security spent the next few months churning in the $4.50--$5.50 range. However, the shares are now on track for their biggest single-session loss since October 2016, and their first close below the 200-day moving average since early March. 

There is ample room for additional downgrades and/or price-target cuts to come down the pike, which could provide more headwinds for the equity. The majority of the brokerages covering the security still rate it a "buy" or "strong buy," and its average 12-month price target of $13.75 is now nearly quadruple PTI's current perch. 

A number of short sellers are likely kicking rocks today. Short interest topped out at a record 3.19 million shares in mid-March, but has since dropped 40% to 1.88 million shares. Nevertheless, this still represents a healthy 13% of PTI's total available float. Short sellers are sitting on the bench today, though, with PTI stock currently on the short-sale restricted list.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners